JPMorgan Chase & Co. Has $28.65 Million Stock Position in Twist Bioscience Corporation $TWST

JPMorgan Chase & Co. lessened its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 29.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,018,234 shares of the company’s stock after selling 420,892 shares during the period. JPMorgan Chase & Co. owned 1.69% of Twist Bioscience worth $28,653,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its holdings in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after buying an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after acquiring an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after acquiring an additional 37,577 shares during the period. Intech Investment Management LLC boosted its holdings in Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in Twist Bioscience by 23.0% in the second quarter. AlphaQuest LLC now owns 7,454 shares of the company’s stock valued at $274,000 after acquiring an additional 1,393 shares during the last quarter.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total value of $249,650.00. Following the transaction, the insider owned 138,581 shares in the company, valued at $6,919,349.33. This trade represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 1,194 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total value of $55,616.52. Following the transaction, the senior vice president directly owned 165,445 shares in the company, valued at approximately $7,706,428.10. The trade was a 0.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,609 shares of company stock valued at $1,665,151 over the last quarter. 3.08% of the stock is currently owned by company insiders.

Twist Bioscience Trading Down 3.7%

NASDAQ TWST opened at $46.92 on Friday. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $57.88. The business has a 50 day moving average price of $42.25 and a 200-day moving average price of $33.93. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -36.66 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on TWST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Barclays boosted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Evercore lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Finally, TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.